Engineering of Nanobodies Recognizing the Human Chemokine Receptor CCR7

Cite This

Files in this item

Checksum: MD5:0e2dbfc86bf4b9d7f12e9ab238d16146

JAKOBS, Barbara D., Lisa SPANNAGEL, Vladimir PURVANOV, Edith UETZ-VON ALLMEN, Christoph MATTI, Daniel F. LEGLER, 2019. Engineering of Nanobodies Recognizing the Human Chemokine Receptor CCR7. In: International Journal of Molecular Sciences. 20(10), 2597. eISSN 1422-0067. Available under: doi: 10.3390/ijms20102597

@article{Jakobs2019-05-27Engin-46455, title={Engineering of Nanobodies Recognizing the Human Chemokine Receptor CCR7}, year={2019}, doi={10.3390/ijms20102597}, number={10}, volume={20}, journal={International Journal of Molecular Sciences}, author={Jakobs, Barbara D. and Spannagel, Lisa and Purvanov, Vladimir and Uetz-von Allmen, Edith and Matti, Christoph and Legler, Daniel F.}, note={Article Number: 2597} }

Legler, Daniel F. Uetz-von Allmen, Edith Purvanov, Vladimir terms-of-use Matti, Christoph Purvanov, Vladimir eng Uetz-von Allmen, Edith 2019-07-18T12:07:31Z Jakobs, Barbara D. 2019-07-18T12:07:31Z Engineering of Nanobodies Recognizing the Human Chemokine Receptor CCR7 Jakobs, Barbara D. Matti, Christoph Legler, Daniel F. The chemokine receptor CCR7 plays a pivotal role in health and disease. In particular, CCR7 controls homing of antigen-bearing dendritic cells and T cells to lymph nodes, where adaptive immune responses are initiated. However, CCR7 also guides T cells to inflamed synovium and thereby contributes to rheumatoid arthritis and promotes cancer cell migration and metastasis formation. Nanobodies have recently emerged as versatile tools to study G-protein-coupled receptor functions and are being tested in diagnostics and therapeutics. In this study, we designed a strategy to engineer novel nanobodies recognizing human CCR7. We generated a nanobody library based on a solved crystal structure of the nanobody Nb80 recognizing the β<sub>2</sub>-adrenergic receptor (β<sub>2</sub>AR) and by specifically randomizing two segments within complementarity determining region 1 (CDR1) and CDR3 of Nb80 known to interact with β<sub>2</sub>AR. We fused the nanobody library to one half of split-YFP in order to identify individual nanobody clones interacting with CCR7 fused to the other half of split-YFP using bimolecular fluorescence complementation. We present three novel nanobodies, termed Nb1, Nb5, and Nb38, that recognize human CCR7 without interfering with G-protein-coupling and downstream signaling. Moreover, we were able to follow CCR7 trafficking upon CCL19 triggering using Nb1, Nb5, and Nb38. Spannagel, Lisa Spannagel, Lisa 2019-05-27

Downloads since Jul 18, 2019 (Information about access statistics)

Jakobs_2-13zy0347kj6w93.pdf 113

This item appears in the following Collection(s)

Search KOPS


My Account